Related references
Note: Only part of the references are listed.Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial (vol 149, pg 521, 2008)
G. Simonneau et al.
ANNALS OF INTERNAL MEDICINE (2009)
Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension
Joanna Pepke-Zaba et al.
CHEST (2008)
The status of Pulmonary Arterial Hypertension in 2008
Harrison W. Farber
CIRCULATION (2008)
Ambrisentan for the treatment of pulmonary arterial hypertension -: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
Nazzareno Galie et al.
CIRCULATION (2008)
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects
Rebecca E. Wrishko et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Endothelin-receptor antagonism: the future is bright
Neeraj Dhaun et al.
LANCET (2008)
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study):: a double-blind, randomised controlled trial
N. Galie et al.
LANCET (2008)
Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension A Randomized Trial
Gerald Simonneau et al.
ANNALS OF INTERNAL MEDICINE (2008)
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil
Gary Burgess et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Medical therapy for pulmonary arterial hypertension - Updated ACCP evidence-based clinical practice guidelines
David B. Badesch et al.
CHEST (2007)
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension
Vallerie V. McLaughlin et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
Robyn J. Barst et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension
TP Singh et al.
AMERICAN HEART JOURNAL (2006)
Sildenafil citrate therapy for pulmonary arterial hypertension
N Galiè et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors
JD Corbin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Ambrisentan therapy for pulmonary arterial hypertension
N Galié et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells
J Wharton et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: Demonstration of a ceiling effect
AE Frost et al.
VASCULAR PHARMACOLOGY (2005)
Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells
B Tantini et al.
BASIC RESEARCH IN CARDIOLOGY (2005)
Clinical efficacy of sildenafil in primary pulmonary hypertension - A randomized, placebo-controlled, double-blind, crossover study
BKS Sastry et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Sitaxsentan therapy for pulmonary arterial hypertension
RJ Barst et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
US healthcare: The intertwined caduceus of physicians, coverage, quality, and cost
A Garson
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Drug therapy: Treatment of pulmonary arterial hypertension
M Humbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Diagnosis and differential assessment of pulmonary arterial hypertension
RJ Barst et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Cellular and molecular pathobiology of pulmonary arterial hypertension
M Humbert et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Pathologic assessment of vasculopathies in pulmonary hypertension
GG Pietra et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Tadalafil in primary pulmonary arterial hypertension
EA Palmieri et al.
ANNALS OF INTERNAL MEDICINE (2004)
Mechanisms of disease: Pulmonary arterial hypertension
HW Farber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Inhaled iloprost for severe pulmonary hypertension
H Olschewski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension - Comparison with inhaled nitric oxide
E Michelakis et al.
CIRCULATION (2002)
Bosentan therapy for pulmonary arterial hypertension
LJ Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension - A double-blind, randomized, placebo-controlled trial
G Simonneau et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
RN Channick et al.
LANCET (2001)
EQ-5D: a measure of health status from the EuroQol Group
R Rabin et al.
ANNALS OF MEDICINE (2001)
Share Paper
